|
Market Closed -
Nasdaq
21:00:00 19/11/2026 GMT
|
5-day change | 1st Jan Change | ||
| 0.6669 USD | -4.17% |
|
-19.36% | -51.32% |
| 11-16 | Allogene Therapeutics, Inc. Presents at UBS Global Biopharma Conference 2026, Nov-16-2026 11:20 AM | |
| 11-09 | Allogene Therapeutics, Inc. - Special Call |
Company Valuation: Allogene Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,126 | 907.1 | 540.2 | 446.6 | 307.9 | 231.1 | - | - |
| Change | - | -57.34% | -40.45% | -17.32% | -31.06% | -24.95% | - | - |
| Enterprise Value (EV) 1 | 1,317 | 330.6 | 91.47 | 234.8 | 347 | -11.03 | 88.16 | -22.83 |
| Change | - | -74.89% | -72.33% | 156.69% | 47.8% | -103.18% | 899.42% | -125.89% |
| P/E | -7.89x | -2.71x | -1.54x | -1.61x | -1.57x | -1.1x | -1.04x | -1.16x |
| PBR | 2.32x | 1.36x | 1.06x | 1.07x | 1.07x | 0.6x | 1.29x | 0.55x |
| PEG | - | -0.1x | 0.16x | 0x | 0x | 0x | -0.16x | 0.1x |
| Capitalization / Revenue | 55.2x | 3,733x | 5,686x | 20,300x | - | 61.1x | 21.8x | 2.91x |
| EV / Revenue | 34.2x | 1,361x | 963x | 10,673x | - | -2.91x | 8.31x | -0.29x |
| EV / EBITDA | -5.37x | -1.03x | -0.29x | -0.96x | -1.76x | 0.05x | -0.37x | 0.09x |
| EV / EBIT | -5.15x | -0.99x | -0.28x | -0.91x | -1.66x | 0.05x | -0.36x | 0.1x |
| EV / FCF | -6.38x | -1.46x | -0.38x | -1.17x | -2.32x | 0.08x | -0.5x | 0.15x |
| FCF Yield | -15.7% | -68.3% | -262% | -85.6% | -43.1% | 1,297% | -200% | 688% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.89 | -2.32 | -2.09 | -1.32 | -0.87 | -0.604 | -0.6424 | -0.5742 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 38.49 | 0.243 | 0.095 | 0.022 | - | 3.784 | 10.61 | 79.32 |
| EBITDA 1 | -245.3 | -321.2 | -313.5 | -243.8 | -197 | -204 | -238.1 | -260.3 |
| EBIT 1 | -255.8 | -335.4 | -327.7 | -257.5 | -209.3 | -208 | -247 | -227 |
| Net income 1 | -257 | -332.6 | -327.3 | -257.6 | -190.9 | -191.3 | -230.3 | -224.2 |
| Net Debt 1 | -809.5 | -576.5 | -448.7 | -211.8 | 39.16 | -242.1 | -142.9 | -253.9 |
| Reference price 2 | 14.9200 | 6.2900 | 3.2100 | 2.1300 | 1.3700 | 0.6669 | 0.6669 | 0.6669 |
| Nbr of stocks (in thousands) | 142,516 | 144,210 | 168,277 | 209,672 | 224,730 | 346,467 | - | - |
| Announcement Date | 23/02/22 | 28/02/23 | 14/03/24 | 13/03/25 | 12/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.1x | -2.91x | 0.05x | -.--% | 231M | ||
| 17.12x | 6.54x | 12.53x | 1.74% | 65.42B | ||
| 31.85x | 8.5x | 28.11x | 0.07% | 58.91B | ||
| 38.62x | 6.88x | 20.55x | 0.84% | 55.24B | ||
| 41.79x | 5.95x | 28.33x | -.--% | 45.66B | ||
| 32.7x | 3.15x | 13.61x | -.--% | 41.29B | ||
| 36.32x | 8.98x | 23.42x | 0.36% | 36.82B | ||
| -18.89x | 54.48x | -20.65x | -.--% | 34.48B | ||
| 41.53x | 8.01x | 26.87x | -.--% | 32.5B | ||
| -89.49x | 16.75x | -96.22x | -.--% | 31.69B | ||
| Average | 13.05x | 11.63x | 3.66x | 0.3% | 40B | |
| Weighted average by Cap. | 18.86x | 11.71x | 8.55x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ALLO Stock
- Valuation Allogene Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
















